Announced
Completed
Financials
Tags
Pharmaceuticals
Minority
Venture Capital
Private
Private Equity
Acquisition
Completed
Domestic
Friendly
drug development
United States
biopharmaceuticals
Synopsis
Bain Capital Life Sciences, a private equity investment firm, led a $250m Series D funding round in Emalex Biosciences, a developer of biopharmaceutical drugs, with participation from Paragon Biosciences, Valor Equity Partners and Fidelity Management & Research Company. "Emalex was founded specifically to tackle serious neurological conditions like Tourette Syndrome, recognizing that drug development for neurologic conditions is exceptionally difficult and few companies are willing to invest in bringing new options to these patients. Our team has a strong track record of success developing neurology drugs and we are pleased to partner with our investors to advance ecopipam for patients," Jeff Aronin, Emalex Founder.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.